Stockscreener 앱 받기
114.22
109.08%
59.59
시간 외 거래:
115.75
1.53
+1.34%
전일 마감가:
$54.63
열려 있는:
$94.93
하루 거래량:
14.30M
Relative Volume:
12.80
시가총액:
$5.94B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
90.65
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
+92.06%
1개월 성능:
+88.54%
6개월 성능:
+146.80%
1년 성능:
+353.43%
1일 변동 폭
$87.58
$117.33
1주일 범위
$53.79
$117.33
52주 변동 폭
$20.84
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
114.22 | 5.94B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Corcept looks to NDA following strong phase III ovarian cancer data - BioWorld MedTech
Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity - insights.citeline.com
Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings) - Benzinga
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast - Benzinga
Why Is Corcept (CORT) Stock Soaring Today - Yahoo Finance
Corcept’s ovarian cancer drug cuts disease progression in study, shares jump By Reuters - Investing.com
Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip - simplywall.st
Corcept's ovarian cancer drug cuts disease progression in study, shares jump - Reuters
NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute - Yahoo Finance
Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer - Endpoints News
Corcept Therapeutics's Options Frenzy: What You Need to Know - Benzinga
Corcept Therapeutics shares surge on positive late-stage ovarian cancer trial results - Proactive Investors
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers - Yahoo Finance
Market movers: Mr Cooper, Newsmax, Corcept Therapeutics... - Proactive financial news
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $150 From $115, Maintains Buy Rating - MarketScreener
Corcept Therapeutics stock soars to all-time high of $95.42 - Investing.com
Corcept soars as ovarian cancer drug succeeds late-stage trial - TradingView
Sector Update: Health Care - TradingView
Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump - Marketscreener.com
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - TradingView
Corcept Therapeutics stock soars after successful Phase 3 trial - Investing.com
Corcept Therapeutics stock soars after successful Phase 3 trial By Investing.com - Investing.com UK
Corcept Therapeutics Says Primary Endpoint Met in Phase 3 Ovarian Cancer Drug Study; Shares Up Pre-Bell - MarketScreener
Corcept's ovarian cancer combination drug meets main goal in late-stage study - TradingView
Corcept reports key trial success in ovarian cancer treatment - Investing.com
Major Clinical Trial Success: New Ovarian Cancer Drug Shows 4.5-Month Survival Advantage - Stock Titan
Did Corcept Therapeutics Incorporated Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateCORT - ACCESS Newswire
NewMax goes public, Corcept Therapeutics gains, Moderna under pressure - Yahoo Finance
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? - Yahoo Finance
Corcept Therapeutics president Sean Maduck sells $102,804 in stock By Investing.com - Investing.com South Africa
Corcept therapeutics officer sells shares worth $25,504 - Investing.com India
Corcept therapeutics CEO Joseph Belanoff sells $120k in stock - Investing.com India
Corcept Therapeutics president Sean Maduck sells $102,804 in stock - Investing.com
3 Reasons to Sell CORT and 1 Stock to Buy Instead - Yahoo Finance
Avantax Advisory Services Inc. Invests $293,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Global Cushing's Syndrome Treatment Market: Research & - openPR
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stake Raised by Natixis Advisors LLC - Defense World
Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR
Research Analysts Offer Predictions for CORT Q1 Earnings - Defense World
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year? - Yahoo
Raymond James Financial Inc. Makes New $12.08 Million Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Proficio Capital Partners LLC Takes $1.60 Million Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud InvestigationCORT - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
Victory Capital Management Inc. Increases Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Charles Schwab Investment Management Inc. Acquires 25,073 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
M&T Bank Corp Sells 1,249 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Armenian Reporter
Corcept therapeutics director sells $117,920 in stock - Investing.com India
Corcept therapeutics director sells $117,920 in stock By Investing.com - Investing.com South Africa
Corcept trial to evaluate Cushing’s and hypertension - Cushing's Disease News
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):